An upper bound on one-to-one exposure to infectious human respiratory particles

Proc Natl Acad Sci U S A. 2021 Dec 7;118(49):e2110117118. doi: 10.1073/pnas.2110117118.

Abstract

There is ample evidence that masking and social distancing are effective in reducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. However, due to the complexity of airborne disease transmission, it is difficult to quantify their effectiveness, especially in the case of one-to-one exposure. Here, we introduce the concept of an upper bound for one-to-one exposure to infectious human respiratory particles and apply it to SARS-CoV-2. To calculate exposure and infection risk, we use a comprehensive database on respiratory particle size distribution; exhalation flow physics; leakage from face masks of various types and fits measured on human subjects; consideration of ambient particle shrinkage due to evaporation; and rehydration, inhalability, and deposition in the susceptible airways. We find, for a typical SARS-CoV-2 viral load and infectious dose, that social distancing alone, even at 3.0 m between two speaking individuals, leads to an upper bound of 90% for risk of infection after a few minutes. If only the susceptible wears a face mask with infectious speaking at a distance of 1.5 m, the upper bound drops very significantly; that is, with a surgical mask, the upper bound reaches 90% after 30 min, and, with an FFP2 mask, it remains at about 20% even after 1 h. When both wear a surgical mask, while the infectious is speaking, the very conservative upper bound remains below 30% after 1 h, but, when both wear a well-fitting FFP2 mask, it is 0.4%. We conclude that wearing appropriate masks in the community provides excellent protection for others and oneself, and makes social distancing less important.

Keywords: COVID-19; SARS-CoV-2; face mask; infection risk; near-field model.

MeSH terms

  • Adult
  • COVID-19 / prevention & control
  • COVID-19 / virology
  • Female
  • Humans
  • Male
  • Masks / virology*
  • Respiratory Tract Infections / prevention & control*
  • Respiratory Tract Infections / virology*
  • SARS-CoV-2 / pathogenicity